Skip to main content

Table 4 Prognostic variables of 246 NPC patients with lung metastasis(es) alone at diagnosis or the first failure.

From: Factors determining the survival of nasopharyngeal carcinoma with lung metastasis alone: does combined modality treatment benefit?

  Post-metastasis survival   Overall survivall
Variables Univariate Analysis P a Multivariate Analysis P a Univariate Analysis P a Multivariate Analysis P a
Age 1.485 (1.097-2.010) 0.010 1.537 (1.038-2.277) 0.032 1.734 (1.277-2.355) < 0.001 1.424 (1.027-1.974) 0.034
Sex 1.018 (0.712-1.458) 0.921 - - 1.022 (0.714-1.463) 0.905 - -
T classification 1.298 (0.948-1.778) 0.104 - - 1.774 (1.281-2.456) 0.001 1.326 (0.936-1.876) 0.112
N classification 1.224 (0.809-1.852) 0.339 - - 1.758 (1.150-2.688) 0.009 1.395 (0.905-2.150) 0.131
M classification 0.938 (0.625-1.408) 0.758 - - 3.010 (1.965-4.612) < 0.001 1.290 (0.766-2.172) 0.338
EBV VCA-lgA 1.490 (1.033-2.148) 0.033 1.342 (0.920-1.958) 0.127 1.348 (0.935-1.942) 0.110 - -
EBV EA-lgA 1.171 (0.803-1.710) 0.412 - - 1.199 (0.820-1.753) 0.349 - -
DFI 0.818 (0.676-0.991) 0.040 1.019 (0.796-1.304) 0.881 0.326 (0.263-0.404) < 0.001 0.379 (0.294-0.490) < 0.001
Metastasis site 1.846 (1.357-2.512) < 0.001 1.295 (0.779-2.153) 0.319 1.964 (1.439-2.682) < 0.001 1.561 (0.967-2.520) 0.068
Metastasis number 1.813 (1.295-2.539) 0.001 1.274 (0.705-2.301) 0.422 1.970 (1.403-2.768) < 0.001 1.284 (0.761-2.097) 0.365
Metastasis size 0.952 (0.699-1.296) 0.754 - - 0.689 (0.505-0.941) 0.019 0.922 (0.664-1.281) 0.629
Recurrence 1.785 (1.125-2.832) 0.014 1.429 (0.778-2.625) 0.250 1.197 (0.755-1.896) 0.444 - -
Treatment modalityb 0.440 (0.302-0.641) < 0.001 0.583 (0.355-0.960) 0.034 0.454 (0.321-0.660) < 0.001 0.566 (0.374-0.857) 0.007
Chemotherapy cyclec 0.828 (0.612-1.122) 0.828 - - 1.143 (0.842-1.552) 0.392 - -
-Chemotherapy effectd 2.305 (1.016-5.228) 0.046 1.243 (0.511-3.026) 0.632 1.603 (0.708-3.627) 0.258 - -
  1. Abbreviation: NPC, nasopharyngeal carcinoma; DFI, disease-free interval.
  2. a Cox proportional hazards analysis.
  3. b Chemotherapy alone vs. combined therapy;
  4. c chemotherapy cycle < 6 vs. chemotherapy cycle ≥ 6;
  5. d Complete remission vs. non-complete remission.